Cargando…

Acquisition of epithelial–mesenchymal transition and cancer stem cell phenotypes is associated with activation of the PI3K/Akt/mTOR pathway in prostate cancer radioresistance

Radioresistance is a major challenge in prostate cancer (CaP) radiotherapy (RT). In this study, we investigated the role and association of epithelial–mesenchymal transition (EMT), cancer stem cells (CSCs) and the PI3K/Akt/mTOR signaling pathway in CaP radioresistance. We developed three novel CaP r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chang, L, Graham, P H, Hao, J, Ni, J, Bucci, J, Cozzi, P J, Kearsley, J H, Li, Y
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2013
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3920940/ https://www.ncbi.nlm.nih.gov/pubmed/24157869 http://dx.doi.org/10.1038/cddis.2013.407

Ejemplares similares

PI3K/Akt/mTOR pathway inhibitors enhance radiosensitivity in radioresistant prostate cancer cells through inducing apoptosis, reducing autophagy, suppressing NHEJ and HR repair pathways
por: Chang, L, et al.
Publicado: (2014)

Drugging the PI3K/AKT/mTOR Pathway in ER+ Breast Cancer
por: Alves, Carla L., et al.
Publicado: (2023)

Targeting the PI3K-AKT-mTOR signaling network in cancer
por: Khan, Khurum H., et al.
Publicado: (2013)

Targeting PI3K/Akt/mTOR Signaling in Cancer
por: Porta, Camillo, et al.
Publicado: (2014)

PI3K/Akt/mTOR inhibitors in breast cancer
por: Lee, Joycelyn JX, et al.
Publicado: (2015)

Silencing c-Jun inhibits autophagy and abrogates radioresistance in nasopharyngeal carcinoma by activating the PI3K/AKT/mTOR pathway
por: Sun, Yongchu, et al.
Publicado: (2021)

Exosomes in Cancer Radioresistance
por: Ni, Jie, et al.
Publicado: (2019)

Sasanquasaponin inhibited epithelial to mesenchymal transition in prostate cancer by regulating the PI3K/Akt/mTOR and Smad pathways
por: Li, Wenfeng, et al.
Publicado: (2022)

Presence of both alterations in FGFR/FGF and PI3K/AKT/mTOR confer improved outcomes for patients with metastatic breast cancer treated with PI3K/AKT/mTOR inhibitors
por: Wheler, Jennifer J., et al.
Publicado: (2016)

PI3K/AKT/mTOR-Targeted Therapy for Breast Cancer
por: Zhu, Kunrui, et al.
Publicado: (2022)

Inhibition of PI3K/Akt/mTOR signaling pathway alleviates ovarian cancer chemoresistance through reversing epithelial-mesenchymal transition and decreasing cancer stem cell marker expression
por: Deng, Junli, et al.
Publicado: (2019)

PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
por: Glaviano, Antonino, et al.
Publicado: (2023)

ANXA6 Contributes to Radioresistance by Promoting Autophagy via Inhibiting the PI3K/AKT/mTOR Signaling Pathway in Nasopharyngeal Carcinoma
por: Chen, Qianping, et al.
Publicado: (2020)

miR-410 induces both epithelial–mesenchymal transition and radioresistance through activation of the PI3K/mTOR pathway in non-small cell lung cancer
por: Yuan, Yue, et al.
Publicado: (2020)

Vertical inhibition of the PI3K/Akt/mTOR pathway is synergistic in breast cancer
por: Woo, S-U, et al.
Publicado: (2017)

mTOR-Mediated Antioxidant Activation in Solid Tumor Radioresistance
por: Woo, Yunseo, et al.
Publicado: (2019)

Inhibition of esophageal cancer growth through the suppression of PI3K/AKT/mTOR signaling pathway
por: Shi, Ni, et al.
Publicado: (2019)

PI3K/AKT/mTOR Pathway in Angiogenesis
por: Karar, Jayashree, et al.
Publicado: (2011)

Therapeutic targets for cancer: Current concepts with PI 3-K, Akt, & mTOR
por: Maiese, Kenneth
Publicado: (2013)

Targeting PI3K/AKT/mTOR Signaling Pathway in Breast Cancer
por: Li, Huayi, et al.
Publicado: (2021)

LncRNA DUXAP8 induces breast cancer radioresistance by modulating the PI3K/AKT/mTOR pathway and the EZH2-E-cadherin/RHOB pathway
por: Lei, Changjiang, et al.
Publicado: (2022)

AKTivation of PI3K/AKT/mTOR signaling pathway by KSHV
por: Bhatt, Aadra P., et al.
Publicado: (2013)

Outlook on PI3K/AKT/mTOR inhibition in acute leukemia
por: Fransecky, Lars, et al.
Publicado: (2015)

Targeting the PI3K/Akt/mTOR signalling pathway in Cystic Fibrosis
por: Reilly, R., et al.
Publicado: (2017)

The PI3K-AKT-mTOR Pathway and Prostate Cancer: At the Crossroads of AR, MAPK, and WNT Signaling
por: Shorning, Boris Y., et al.
Publicado: (2020)

The Role of PI3K/AKT/mTOR Signaling in Hepatocellular Carcinoma Metabolism
por: Tian, Ling-Yu, et al.
Publicado: (2023)

Akt and mTOR mediate programmed necrosis in neurons
por: Liu, Q, et al.
Publicado: (2014)

The PI3K/Akt/mTOR pathway in ovarian cancer: therapeutic opportunities and challenges
por: Cheaib, Bianca, et al.
Publicado: (2015)

Inhibitors of the PI3K/Akt/mTOR Pathway in Prostate Cancer Chemoprevention and Intervention
por: Roudsari, Nazanin Momeni, et al.
Publicado: (2021)

Bioactive PI3-kinase/Akt/mTOR Inhibitors in Targeted Lung Cancer Therapy
por: Ghareghomi, Somayyeh, et al.
Publicado: (2023)

PI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance
por: Edlind, Merritt P, et al.
Publicado: (2014)

Aspirin increases the efficacy of gemcitabine in pancreatic cancer by modulating the PI3K/AKT/mTOR signaling pathway and reversing epithelial‑mesenchymal transition
por: Zhou, Hanyu, et al.
Publicado: (2023)

Nrf3 promotes the proliferation and migration of triple‑negative breast cancer by activating PI3K/AKT/mTOR and epithelial‑mesenchymal transition
por: Chen, Wan-Meng, et al.
Publicado: (2023)

Ovalitenone Inhibits the Migration of Lung Cancer Cells via the Suppression of AKT/mTOR and Epithelial-to-Mesenchymal Transition
por: Sanookpan, Kittipong, et al.
Publicado: (2021)

Wnt and PI3K/Akt/mTOR Survival Pathways as Therapeutic Targets in Glioblastoma
por: Barzegar Behrooz, Amir, et al.
Publicado: (2022)

CircCASC15-miR-100-mTOR may influence the cervical cancer radioresistance
por: Yao, Tingting, et al.
Publicado: (2022)

PIM Kinases and Their Relevance to the PI3K/AKT/mTOR Pathway in the Regulation of Ovarian Cancer
por: Aziz, Aziz Ur Rehman, et al.
Publicado: (2018)

PI3K/AKT/mTOR Pathway in Ovarian Cancer Treatment: Are We on the Right Track?
por: Gasparri, Maria Luisa, et al.
Publicado: (2017)

Targeting the PI3K/AKT/mTOR/NFκB Axis in Ovarian Cancer
por: Ghoneum, Alia, et al.
Publicado: (2020)

Signal Transduction Pathways in Breast Cancer: The Important Role of PI3K/Akt/mTOR
por: Ortega, Miguel A., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ifb87j4qdnc564sdt6v90ls4nb